The U.S. FDA approved Carboprost tromethamine  in 2019. Carboprost tromethamine is  known as synthetic prostaglandin. It is used to treat postpartum (after giving birth) bleeding caused by atony of the uterus (soft and weak uterus after childbirth) in women. It is not a self-administered medicine; your doctor will decide the dosage of the drug based on your health history under proper monitoring of your health condition.

Carboprost tromethamine is used for postpartum hemorrhage (stop the excessive bleeding in women who have just given birth)

Inform your doctor about any prescribed medications, over-the-counter medicines, nutritional or vitamin supplements, and herbal products you take or have taken before the treatment. Certain medications may interact with carboprost tromethamine and can cause undesirable side effects. 

The common side effects that are experienced while you are on the treatment with Carboprost tromethamine diarrhea, nausea, vomiting, increased body temperature, headache, flushing, hot flushes, chills, cough, uterine bleeding, and potential complications such as retained placenta or membranes, as well as endometritis. 

Consult your doctor if you are allergic to carboprost tromethamine or any ingredients, and inform your doctor if you have acute pelvic inflammatory disease. Consult your doctor if you are planning to get pregnant or think you may be pregnant or while breastfeeding because it is contraindicated for pregnant women.

The safety and effectiveness of children and the elderly are not established. They are also contraindicated for patients with heart, liver, lung, and kidney problems, diabetes, jaundice, anemia, problems in blood pressure, and epilepsy.

It is recommended to talk with your doctor if you are under carboprost tromethamine medication and your prescribed and non-prescribed medicine. As this drug may increase the cardio-pulmonary problem, your doctor will monitor your health and give you extra oxygen if needed. Patients with a history of allergic reactions should inform their doctor.

1. Pfizer Limited, Electronic Medicines Compendium (EMC), [Revised on May 2022] [Accessed on 7 Oct 2023], https://www.medicines.org.uk/emc/product/3828/pil
2. Pfizer, US Food and Drug Administration, [Revised on Dec 2013], [Accessed on 28th Sep 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050141s237lbl.pdf
3. KD Tripathi, Essentials of Medical Pharmacology, Prostaglandins, Leukotrienes and Platelet activating factor, 7th edition, 2013, 189.

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details consult your doctor about your medical condition to know if you are eligible to receive this treatment.